看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
6 X7 Z2 i! C8 L% c+ H* r+ ~6 X2 h+ [ j$ a% T
+ N6 Q4 Y7 u; QCurrently available feasibility data for possible combination strategies.
& u$ G/ h$ C! o: \8 e; I————————————————————————————————
# ?+ a6 @* d/ b/ [; xCombination Feasibility according to preliminary data " ]' x) u" a# p: Z6 L0 a+ t2 J" f
——————————————————————————————————2 l) ~. ^, u# Z4 b" M
Bevacizumab + sorafenib Yes, reduced dose 0 P# U( L9 C+ O. J3 I. s
Bevacizumab + sunitinib† No 9 F1 c( f+ ^0 B D, J
Bevacizumab + temsirolimus Yes
) }0 J5 t; G9 r4 ^9 U% ?6 u! rBevacizumab + everolimus Yes
7 n* x0 p* @; r' {3 R: g7 ]Sorafenib + sunitinib ? & s; T: O L y/ E$ X5 r! ]
Sorafenib + temsirolimus Yes, reduced dose
^4 ?+ D1 t( M+ R3 E. W4 nSorafenib + everolimus Yes, reduced dose
4 |: i$ X" T5 I6 G' rSunitinib + temsirolimus† No
[) H$ L' R; LSunitinib + everolimus ? & \ h3 T" X& c; f" J) R; r
Temsirolimus + everolimus ? ; i' v& Z: w& T5 h
————————————————————0 v1 q+ Z- b5 H8 ]0 t% A% W
†Led to US FDA warning.; h# |* B+ X8 k
?: As yet unattempted combination.
5 R2 F% P+ G$ p8 S Y: d0 K/ H |